Branded generics' as a strategy to limit cannibalization of pharmaceutical markets

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 251-265

  Reiffen, David ^a   Ward, Michael R ^b  

^a Office of the Chief Economist   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548310318     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1339     Document Type: Article

References (20)

1. Berndt E, Bui L, Reilly D, Urban G. 1995. Information, marketing, and pricing in the U.S. antiulcer drug market. American Economic Review 85: 100-105.
2. Bond R, Lean D. 1977. Sales, promotion and product differentiation in two prescription markets. Staff Report to the Federal Trade Commission, Washington, DC.
3. Caves R, Whinston M, Hurwitz M. 1991. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics, 1-66.
4. CibaGeneva Pharmacy Benefit Report. 1995. Trends and Forecast. CibaGeneva Pharmaceuticals, Summit, NJ.
5. Cook A. 1998. How Increase Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry. Congressional Budget Office Study.
6. DiMasi J, Hansen R. Grabowski H. 2003. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 22: 151-185.
7. Frank R, Salkever D. 1997. Generic entry and the pricing of pharmaceuticals. Journal of Economics and Management Strategy 6: 75-90.
8. Goldsmith J. 2002. Essays on consumer access to new products and technologies. Doctoral Dissertation, University of Maryland.
9. Grabowski H, Vernon J. 1992. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35: 331-351.
10. Grabowski H, Vernon J. 1994. Returns to R&D on new drug introductions in the 1980s. Journal of Health Economics 13: 383-406.
11. Goldberg G. 1994. Will there be a generic industry five years from now? Medical Marketing and Media 32: 33-38.
12. Hollis A. 2003. The anticompetitive effects of brand-controlled 'pseudo-generics' in the Canadian pharmaceutical market. Canadian Public Policy 29: 21-32.
13. Kong Y, Seldon J. 2004. Pseudo-generics and entry in pharmaceutical markets. Review of Industrial Organization 25: 71-86.
14. Levy R. 1999. The pharmaceutical industry: a discussion of competitive and antitrust issues in an environment of change. Bureau of Economics Staff Report, Federal Trade Commission.
15. Liang B. 1996. The anticompetitive nature of brandname firm introduction of generics before patent expiration. Antitrust Bulletin 41: 599-635.
16. Muirhead G. 1994. HMOs are controlling more and more prescriptions. Drug Topics 138(21): 72.
17. Quinn K. 1998. The Sources and Types of Health Insurance: Comprehensive Population Counts for 1985 to 1993. Apt Associates: Bethesda, MD.
18. Reiffen D, Ward M. 2005. Generic drug industry dynamics. Review of Economics and Statistics 87: 37-49.
19. Scott Morton F. 1996. Entry decisions in the generic pharmaceutical industry. RAND Journal of Economics 30: 421-440.
20. Wiggins S, Maness R. 2004. Price competition in pharmaceuticals: the case of anti-infectives. Economics Inquiry 42: 247-263.